Electron Therapy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Electron beam therapy is a form of external beam radiotherapy that uses high-energy electrons (6–20 MeV) — rather than photons (X-rays) — to deliver ionising radiation. The fundamental physical advantage of electrons is their finite range in tissue: after depositing most of their energy in the first few centimetres of tissue, electrons rapidly lose energy and stop. This sharp dose fall-off makes electrons ideal for treating superficial tumours and target volumes close to the skin surface while protecting underlying critical structures such as the lung, spinal cord, and heart. Electron beams are generated by linear accelerators (linacs) that switch between photon and electron modes. Beam energy selection (6–20 MeV) controls the treatment depth — the 80% isodose depth in centimetres approximately equals the energy in MeV divided by three. Electron therapy is delivered by radiation therapists (radiographers) on a linear accelerator and planned by clinical medical physicists and radiation oncologists using specialised dose calculation software. Over 20,000 patient courses of electron beam therapy are delivered annually in UK NHS radiotherapy centres. Modern electron therapy planning uses Monte Carlo dose calculation algorithms for accurate modelling of dose distributions at tissue interfaces, replacing older pencil-beam algorithms that underestimated dose heterogeneity.

Electron therapy is indicated for: cutaneous malignancies — squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and Merkel cell carcinoma — particularly on the scalp, face, and extremities where surgery would cause poor cosmetic or functional outcomes; post-mastectomy chest wall irradiation for locally advanced breast cancer (reducing locoregional recurrence by approximately 50%); cutaneous lymphoma (mycosis fungoides), where total skin electron beam therapy (TSEBT) treats the entire skin surface; adjuvant radiotherapy for sarcoma of superficial soft tissues; keloid scar prophylaxis after excision; and irradiation of superficial lymph node regions (supraclavicular, axillary) in patients where photon depth would irradiate underlying lung or brachial plexus. Total skin electron beam therapy (TSEBT) is the only treatment that can address the entire skin surface simultaneously for cutaneous T-cell lymphoma affecting the whole integument.

A radiation oncologist plans electron therapy using CT simulation. The appropriate energy (6–20 MeV) is selected based on tumour depth. A custom lead or Cerrobend cut-out shapes the electron field to conform to the target volume and protect adjacent uninvolved skin. Bolus — water-equivalent tissue-like material (e.g., Superflab) — is placed on the skin surface to shift the depth-dose curve and bring the maximum dose closer to the surface for very superficial targets. Each fraction takes 10–20 minutes at the linac; the patient lies still while the beam is delivered. Standard fractionation for skin SCC/BCC is 50–60 Gy in 15–25 fractions over 3–5 weeks. Post-mastectomy chest wall treatment typically delivers 40–50 Gy in 15–25 fractions. Modern planning systems calculate electron dose distributions using Monte Carlo algorithms for accurate dosimetry at irregular tissue interfaces. The radiation therapist aligns the patient using room lasers and skin tattoo marks applied at simulation, ensuring millimetre reproducibility at each fraction. Electron energy selection is guided by the rule that the 80% dose depth (in cm) approximately equals the energy (in MeV) divided by three — so a 9 MeV beam treats to approximately 3 cm depth, while a 6 MeV beam reaches approximately 2 cm. Shielding of sensitive structures within the field — such as the eye lens during orbital treatments or the underlying lung during chest wall irradiation — uses internal or external lead shielding positioned by the radiation therapist. Thermoluminescent dosimetry (TLD) or MOSFET dosimetry is used to verify the delivered dose on the patient's skin surface during the first fraction.

Electron therapy achieves local control rates of 85–95% at 5 years for skin SCC and BCC — comparable to Mohs surgery for selected cases — without scarring, particularly valuable for lesions on the nose, ear, eyelid, or scalp where surgery causes cosmetic deformity. Post-mastectomy chest wall electron irradiation reduces locoregional recurrence by approximately 50% in high-risk patients (four or more positive nodes, T3–T4 tumours), improving disease-free survival. TSEBT for mycosis fungoides achieves complete skin response in 60–80% of early-stage patients. Electron therapy spares deep structures more effectively than photon X-ray therapy for superficial targets — cardiac and pulmonary doses are substantially lower with electrons in left-sided breast cancer chest wall irradiation. Electron therapy is typically completed on an outpatient basis, allowing patients to maintain normal daily activities throughout treatment.

Acute skin reactions develop during weeks 2–5 of treatment: erythema (redness), dry desquamation (peeling), and in higher doses, moist desquamation (weeping skin breakdown) in the treatment field. These reactions peak 1–2 weeks after treatment ends and heal within 4–6 weeks with aqueous cream, wound dressings, and avoidance of UV exposure. Fatigue during and for 4–8 weeks after treatment is common. Late effects are uncommon but include: skin fibrosis (thickening), telangiectasia (dilated superficial vessels), hyperpigmentation or hypopigmentation, and hair loss within the treatment field (permanent at higher doses). Electron therapy significantly reduces the risk of cardiac and pulmonary late toxicity compared to photon X-ray for chest wall irradiation — a major clinical advantage for long-term breast cancer survivors. Reactions are graded and documented at each weekly on-treatment review.

Patients attend daily (Monday–Friday) for the duration of fractionated treatment — typically 3–6 weeks — returning home immediately after each fraction. Aqueous cream or prescribed barrier creams are applied generously throughout treatment and for 4 weeks afterwards to manage skin reactions. Sun protection (SPF50+ sunscreen and protective clothing) over the treatment area is essential indefinitely, as irradiated skin is permanently more sun-sensitive. The treatment field is marked with permanent skin tattoo dots for reproducibility throughout the treatment course. At the end of treatment, skin reaction assessment continues at a follow-up appointment 4–6 weeks post-completion. Ongoing surveillance (3–6 monthly for 2 years, then annually) monitors for tumour recurrence and late effects. Long-term follow-up is arranged by the radiation oncology team at 3, 6, and 12 months post-treatment.